In conclusion, our findings indicate that H+, K+-ATPases are promising targets in pancreatic ductal adenocarcinoma and that treatment with proton pump inhibitors or P-CABs could be a useful therapeutic strategy worthwhile of testing in a carefully controlled clinical settings. The gene discussed is ATP12A; the disease is pancreatic ductal adenocarcinoma.